Ramipril is a prescription ACE inhibitor used for high blood pressure, heart failure and selected care after a heart attack. Confidence in these clinical roles is high; this review supplies no independent best-drug ranking. NHS purpose.
- Kidney function, potassium and blood pressure need an agreed monitoring plan.
- Face, tongue or throat swelling needs emergency assessment; a dry cough is a different problem.
- If pregnancy occurs, stop ramipril and contact the doctor immediately for an alternative plan.
- Potassium products, painkillers and other heart medicines require an interaction review.
- Confirm the local product, formulation and licence.
Table of contents
- Evidence summary
- Ramipril products
- ACE inhibition and blood-pressure control
- Licensed indications
- Lifestyle, salt substitutes and supplements
- HOPE: original methods, funding and limits
- Urgent warnings
- Interactions and contraindications
- Pregnancy and breastfeeding
- Taking ramipril, illness and monitoring
- Laboratory evidence and safety reporting
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Purpose? | NHS purpose. | Public contributor/trial chain unclosed. | Prescription context; no personal selection. |
| Where does it fit? | 2025 AHA/ACC class framework. | Society funding and connected authors, Tier 3/C. | Attributed care guidance; trial chains not cleared. |
| What did HOPE study? | Original randomised methods/support. | Public and commercial backers, Tier 4/D. | Methods/funding only; efficacy estimates excluded. |
| What needs monitoring? | Current SPS professional framework. | Commissioned service; host/author chains unclosed. | Kidneys, electrolytes and pressure; individual plan. |
| Breastfeeding? | Labels and SPS. | Maker/public chains differ. | Infant-specific specialist decision. |
Ramipril products
Ramipril comes in tablets, capsules and oral liquid. Confirm the ingredient, strength and preparation on the supplied pack; a combination product needs separate review. Preparations.
The reviewed UK Tritace record covers ramipril tablets. UK identity.
US Altace capsules are labelled by Pfizer. Licensed roles include hypertension, selected cardiovascular prevention and stable post-infarction heart failure. Older pack-end dates limit availability claims. US record.
England recorded 36,339,463 ramipril community prescription items in FY 2025/26, BNF code 0205051R0. Original substance row.
PCA includes hospital-issued prescriptions dispensed in the community, but excludes hospital dispensary supplies. Items are not people, indications, clinical quality or worldwide popularity. Counting scope.
For a comparison of medicine families, see Blood Pressure Medicines. This guide addresses the individual ingredient rather than every ACE inhibitor or combination pack.
ACE inhibition and blood-pressure control
Ramipril inhibits angiotensin-converting enzyme, relaxing and widening blood vessels. A lower pressure during treatment can reflect control; do not stop the prescription yourself. Mechanism and continuity.
A biological mechanism is different from a demonstrated clinical outcome. It does not establish which medicine is best for a particular person, whether two formulations are interchangeable or how much treatment that person needs. A useful clinical comparison specifies the population, alternative treatment, outcome and follow-up, then checks the original study’s financial relationships.
Licensed indications
UK indications include hypertension, symptomatic heart failure, selected cardiovascular prevention, specified proteinuric kidney conditions and post-infarction heart failure. Licensed roles.
The 2025 AHA/ACC hypertension guideline includes ACE inhibitors among initial medicine classes. Selection considers coexisting conditions. This is attributed guidance with disclosed author interests, not an independently cleared ramipril superiority verdict. Class-selection framework.
Ask which indication applies, who reviews treatment and how progress will be judged. The same ingredient may be prescribed for different problems. A medicine list cannot substitute for the diagnosis, kidney results, other prescriptions and history of reactions that inform clinical selection. Neither this guide nor the prescribing count provides a home treatment algorithm.
Lifestyle, salt substitutes and supplements
NHS hypertension advice supports a balanced diet, appropriate activity, weight management, less salt, smoking cessation and alcohol review. Feeling well does not replace assessment because hypertension may have no symptoms. Condition advice.
Potassium-containing salt substitutes can raise potassium with ramipril. Alcohol can increase dizziness; avoid driving or machinery while impaired. Food and impairment cautions.
There is limited information about combining herbs or supplements with ramipril. Tell the pharmacist about the actual product and ingredients. Supplement limits.
No independently cleared supplement replacement, “natural ACE inhibitor”, brand ranking or cough remedy is established here. A supplement’s effect on a laboratory marker would not prove fewer serious events. Bring its label to the review, including minerals, mixtures and products sold for fitness or relaxation. Agree practical dietary changes with the team rather than independently restricting entire food groups.
HOPE: original methods, funding and limits
HOPE randomised higher-risk adults to ramipril or placebo within a factorial study involving vitamin E. It used a composite of heart attack, stroke or cardiovascular death. Its run-in excluded some people before randomisation; people with known heart failure were excluded. The population is not every person prescribed ramipril. Original study design.
Commercial funding places HOPE in Tier 4/D; benefit estimates are excluded from the independent verdict.
This financial classification does not show that every reported result is false, or that prescribed treatment has no benefit. It defines the limits of this review. An independent steering or monitoring committee and randomised methods are separate from the original source of money. A later publicly funded review cannot remove the sponsorship of an underlying trial. No personal benefit probability or ranking against other ACE inhibitors is supplied.
Urgent warnings
A persistent dry cough should be reviewed; cough medicines may not help. Dizziness can affect driving and falls, especially after starting or changing treatment. Reported effects.
Swollen lips, tongue, face or throat, difficulty breathing or swallowing, collapse, concerning chest pain or new stroke-like symptoms need the local emergency service. Do not drive yourself. Emergency signs.
Jaundice, severe abdominal pain, unusual bleeding/infections or little/no urine need prompt medical assessment. A symptom list cannot prove ramipril caused an event. Other serious signs.
Suspected angioedema: stop ramipril and seek emergency help. It can occur anytime; intestinal angioedema can cause abdominal pain without previous facial swelling. Specific warning.
Bring the medicine pack if doing so will not delay care.
Interactions and contraindications
NSAIDs such as ibuprofen, potassium-raising treatments, lithium and other medicines affecting blood pressure or kidneys need review. This is not a complete interaction checker. Selected medicine cautions.
Do not combine Tritace with sacubitril/valsartan; switching needs a professional plan. Contraindications include prior angioedema and significant renal-artery narrowing affecting both kidneys or a single functioning kidney. Contraindications.
The leaflet also flags transplant medicines, diabetes treatments and lithium: glucose or lithium monitoring may need adjustment by the responsible service. Additional cautions.
Present the complete medicine list before a new antibiotic, painkiller or heart-failure treatment is added. Include nonprescription products and recent changes. Do not borrow a tablet, start a potassium product, stop another necessary medicine or calculate your own switching interval. A medicine being available from a pharmacy does not make every combination suitable.
Pregnancy and breastfeeding
Discuss dialysis, kidney/liver/heart problems, unstable pressure, recent vomiting/diarrhoea and planned anaesthesia. In diabetes, glucose monitoring may need closer review. Suitability depends on the specific problem, not simply the presence of a kidney diagnosis. Medical history.
Plan pregnancy with the treating team. If already pregnant, stop ramipril and contact the doctor straight away for an alternative plan; do not wait until a later trimester. Immediate pregnancy warning.
UK Tritace does not recommend breastfeeding use. UK label.
US Altace also does not recommend breastfeeding use. US label.
SPS permits cautious ramipril use for full-term healthy infants, with enalapril preferred. Evidence is limited. Monitor poor feeding/weight gain, drowsiness, pallor and urine output. Premature/unwell infants or multiple medicines need specialist advice. Professional scope.
Reconcile these sources with the specialist; do not switch yourself.
Taking ramipril, illness and monitoring
Follow the actual prescription and supplied leaflet. Use the provided measuring device for liquid, not a kitchen teaspoon; do not double a missed dose. Seek immediate medical advice after more than the prescribed amount is taken. Taking and overdose advice.
Vomiting, severe diarrhoea or illness with fever/sweating calls for advice. The team may recommend a temporary change; use an agreed illness plan or contact the service rather than applying a universal stop/restart rule. Illness advice.
SPS recommends baseline blood pressure, kidney function, potassium and sodium checks, with reassessment after starting/changing treatment and during relevant acute illness. The indication and other risks affect follow-up. Abnormal results require professional interpretation. Monitoring framework.
An appropriate cuff, supported arm and repeat measurements help reliable blood-pressure measurement. Agree a recording plan; a single home result is not a dose instruction. Measurement advice.
Confirm who orders tests and communicates results. Bring the pack, readings and symptom timeline. Tell the procedure team about ramipril; coordinate any change with the prescriber. This guide provides no dose, laboratory threshold, target pressure or procedure interval.
Laboratory evidence and safety reporting
Animal and cell findings do not establish clinical benefit, a safe human dose or a retail preparation’s suitability. They are excluded from this guide’s clinical verdict. A result in a laboratory cannot replace an appropriately designed human study and its financial assessment.
Yellow Card can receive suspected adverse-effect reports. Reporting is separate from medical care; a report does not by itself prove causation or establish a personal incidence rate. Reporting service.
The funding map distinguishes a source institution’s revenue, a product holder, a researcher’s declared relationship and a particular trial’s sponsor. A permitted gift is not evidence of a donation, and a later corporate acquisition is not evidence of an original trial payment. Unverified allocations remain unverified.
Funding and source roles
Research funding at a glance
39 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS ramipril: purpose | Website funding policy. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. March 18, 2026. Selected education; no independent comparative efficacy. |
| NHS ramipril: adverse effects | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. March 18, 2026. Selected education; no independent comparative efficacy. |
| NHS ramipril: interactions | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | C provisional. March 18, 2026. Selected education; no independent comparative efficacy. Erroneous drug grouping excluded. |
| NHS ramipril: pregnancy | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | C provisional. March 18, 2026. Selected education; no independent comparative efficacy. Delayed-stop wording excluded. |
| NHS ramipril: taking | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. March 18, 2026. Selected education; no independent comparative efficacy. |
| NHS ramipril: questions | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | C provisional. March 18, 2026. Selected education; no independent comparative efficacy. Procedure timing and review-date anomalies excluded. |
| NHS ramipril: suitability | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. March 18, 2026. Selected education; no independent comparative efficacy. |
| NHS high blood pressure | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. July 2024. Selected education; no independent comparative efficacy. |
| NHS blood pressure test | Shared NHS website funding route below. Page/contributor/trial interests unclosed. | United Kingdom; national NHS website. | Tier 2; public context, provisional | B provisional. November 2025. Selected education; no independent comparative efficacy. |
| Tritace UK SmPC, August 2026 | Aventis Pharma Ltd trading as Sanofi, Reading. Revenue. | United Kingdom. | Tier 4; manufacturer | D. Indications/safety; efficacy excluded. |
| Tritace leaflet, November 2020 | Sanofi holder, Reading; Sanofi S.r.l. listed plant, Scoppito, Italy. Actual pack unverified. | United Kingdom leaflet; dated Italian plant. | Tier 4; manufacturer source | D. Dated selected cautions, corroborated by current SmPC; no availability claim. |
| Altace US label, May 2026 | Pfizer Laboratories. Revenue; Host finance. | United States. | Tier 4; manufacturer | D. Indications/safety; efficacy excluded. |
| SPS ACE-inhibitor monitoring | Commissioning route. Hosts, contributors, page allocation and underlying trials unclosed. | United Kingdom NHS service. | Tier 2; clinical context, provisional | B provisional. August 12, 2026 update; individualized professional monitoring, no home thresholds. |
| SPS ACE inhibitors and breastfeeding | Service route. Host/author/page/study finances unclosed. | United Kingdom clinical advice. | Tier 2; clinical context, provisional | B provisional. June 2023; limited evidence and full-term healthy-infant scope. |
| AHA/ACC hypertension guideline, 2025 | Society-sponsored, no commercial writing support reported. Development-period Ferdinand consulting includes Sanofi, Amgen, Janssen, Medtronic, Novartis; other relationships disclosed. AHA finance; ACC routes. | United States framework. | Tier 3; connected guideline authors | C provisional. Preamble, selected framework and writer declarations; peer/underlying-trial chains unclosed. |
| HOPE original paper, 2000 | Medical Research Council of Canada; Hoechst–Marion Roussel, AstraZeneca, King Pharmaceuticals, Natural Source Vitamin E Association/Negma; Heart and Stroke Foundation of Ontario. Yusuf reports public award/chair. Seller route; Later acquisition. | Canadian coordination; multinational backers/sites. Historical backer HQ chains unclosed. | Tier 4; manufacturer-funded research | D. Randomisation does not erase sponsorship; complete historical author/backer payments unclosed. Efficacy excluded. |
| Sanofi results, January 2026 | Medicine/vaccine sales; shareholder dividends and buybacks. Share/office record. | France; Paris group office separately documented. | Tier 4; seller financial source | D. Own 2025 results, not full audited ledger or historical trial payments. |
| Sanofi share and office record | Share capital/voting disclosure under French corporate rules; no exact ramipril budget. | France; 46 avenue de la Grande Armée, Paris registered office. | Tier 4; seller institutional record | D. Actual current shareholder/office record; not a generic manufacturer census. |
| Pfizer annual review, 2025 | Medicine/vaccine/alliance revenue and public shareholders. Current headquarters. | United States company. | Tier 4; seller financial source | D. Own current financial summary; no exact ramipril or historical personal payment. |
| Pfizer current fact sheet | NYSE-listed pharmaceutical business; trial/label budget not supplied. | United States; 66 Hudson Yards, New York headquarters. | Tier 4; seller identity source | D. Actual current business/location; financial context only. |
| Pfizer acquisition of King, 2011 | Company states completed cash/shareholder acquisition; King became a subsidiary. Current finance. | United States companies; dated corporate transaction. | Tier 4; seller historical source | D. Ownership history, not evidence Pfizer paid the original HOPE budget. |
| AstraZeneca annual summary, 2025 | Medicine commercialisation, shareholder revenue/dividends. Dated office record. | United Kingdom public company. | Tier 4; seller financial source | D. Current own summary, not complete historical HOPE allocations. |
| AstraZeneca AGM notice, 2025 | Shareholder and corporate-registration record. | United Kingdom; Cambridge Biomedical Campus registered office, February 2025. | Tier 4; seller institutional source | D. Dated office provenance only; current individual trial payments unclosed. |
| England PCA substances, 2025/26 | Agency accounts. Exact statistical allocation/contributor interests unclosed. | England community dispensing. | Tier 2; public statistics, provisional | B provisional. Original workbook row/cells checked; items do not establish benefit. |
| PCA methodology, June 2026 | Agency finance. Exact programme allocation unclosed. | United Kingdom; England dataset. | Tier 2; public definitions, provisional | B provisional. Actual scope/counting units; not global prescribing. |
| MHRA Yellow Card | Regulator finance. Exact reporting-service budget/interests unclosed. | United Kingdom regulator. | Tier 3; reporting context, provisional | B provisional. Suspected events, not causation/incidence; medical care comes first. |
| NHSBSA accounts, 2025/26 | DHSC Parliamentary funding plus operating service/contract income; student-support receipts separately treated. Exact PCA allocation not identified. | United Kingdom; Newcastle upon Tyne. | Tier 3; own financial report | B provisional. Statutory accounts; selected funding notes read. Institutional route only. |
| NHS content policy | DHSC website funding stated; no advertising/corporate sponsorship; contributor declarations required. Policy reviewed 2022, review due 2025. | United Kingdom; national NHS website. | Tier 3; own policy | B provisional. Public accountability; overdue policy review and public contributor-register gaps. No trial clearance. |
| SPS service commissioning | NHS England commissioning with nine host trusts/subcontractors. Published arrangements run to 31 March 2026; renewal and individual provider money unclosed. | United Kingdom; distributed providers, no single HQ verified. | Tier 3; own service statement | B provisional. Contract disclosure; dated coverage does not clear each author/page. |
| NHS England accounts, 2025/26 | DHSC grant-in-aid principally; additional service, research and consolidated charge/other income. Parent and consolidated routes differ; SPS allocation unidentified. | United Kingdom; Leeds contact address. | Tier 3; own financial report | B provisional. Selected notes read; commissioner finances do not replace host-trust ledgers. |
| MHRA accounts, 2025/26 | DHSC grant-in-aid plus statutory industry fees, customer/service income, research grants and biological-standard sales. | United Kingdom; London/Canary Wharf and South Mimms sites. | Tier 3; own financial report | B provisional. Selected current income notes read; exact safety-alert allocation unclosed. |
| NLM FY 2027 justification | FY 2026 enacted funding distinguished from FY 2027 request. Institutional grants/contracts/intramural routes; DailyMed allocation and individual gifts unclosed. | United States; Bethesda NIH library. | Tier 3; own budget report | B provisional. Selected actual budget table read; public hosting does not make labels independent. |
| NLM appropriations index | Congressional justification index; 2026 consolidation described as a proposal. Current 2027 original separately read above. | United States; 8600 Rockville Pike, Bethesda. | Tier 3; own institution record | B provisional. Location/index only; no completed restructuring inferred. |
| NIH gift-administration policy | Conditional/unconditional gift authority with conflict checks; supplementary routes include authorised foundation transfers. Authority does not establish a named NLM donation. | United States; NIH-wide policy. | Tier 3; own financial policy | B provisional. Actual policy read; donor receipts and exact medicine-page allocations unclosed. |
| AHA annual report, 2024/25 | Contributions, events, bequests and other public support; training/product/services revenue. Corporate route. | United States; Dallas headquarters separately documented. | Tier 3; own financial report | B provisional. Selected financial highlights; exact guideline allocation unclosed. |
| AHA corporate disclosure, 2024/25 | Corporate gifts/events/programme fees include pharmaceutical, biotech and device routes; earned/committed support may differ from cash. | United States society. | Tier 3; own financial disclosure | C provisional. Actual one-page route read; complete donor list and guideline allocation unclosed. |
| AHA fundraising notices | Nonprofit state-registration/accountability notices, not a guideline grant ledger. | United States; New York incorporation; principal headquarters Dallas, Texas. | Tier 3; own institutional record | B provisional. Actual identity/location; no individual author clearance. |
| ACC industry relations | Pharma/device/equipment grants. ACCF charitable education; ACC/ACCF sponsorship/promotion/advertising; ACC exhibits. | United States; Washington, DC contact separately documented. | Tier 3; own commercial-support statement | C provisional. Actual routes read; full ledger and exact guideline allocation unclosed. |
| ACC contact record | Institutional office record; finance separately documented above. | United States; 2400 N Street NW, Washington, DC. | Tier 3; own contact record | B provisional. Contact provenance, not trial independence. |
Frequently asked questions
Can I stop when my blood pressure is lower? A lower reading during treatment is not a home stopping rule. NHS context.
What if I become pregnant while taking ramipril? Stop it and contact the doctor immediately for an alternative plan. Pregnancy advice.
Can I take potassium salt substitutes? They can raise potassium with ramipril; check the actual product with the pharmacist. Potassium caution.
Can ramipril be used while breastfeeding? SPS is cautious; labels differ. Reconcile with the specialist. Scope limits.
Is Altace currently available? The record cannot confirm stock. Pack dates.
Sources and funding notes
UK SmPC text: August 25, 2026; US label: May 2026. The November 2020 leaflet is dated context, corroborated against the current SmPC. HOPE’s full nine-page original replica was read for methods and funding; its benefit estimates were excluded. Selected clinical/preamble and writer-declaration passages of the full 2025 guideline were read; complete underlying trial/peer chains remain unclosed. The SPS funding page’s displayed contract period ends March 2026; renewed contract details were not verified. Current institutional accounts and seller revenue do not assign exact page budgets, historical cheques or personal payments. The supplied pack and local care govern decisions.
- NHS ramipril: purpose — Prescription context
- NHS ramipril: adverse effects — Symptoms and urgent care
- NHS ramipril: interactions — Selected interactions; classification errors excluded
- NHS ramipril: pregnancy — Immediate pregnancy action; delayed-stop wording excluded
- NHS ramipril: taking — Taking, illness and overdose
- NHS ramipril: questions — Mechanism, potassium and procedure context
- NHS ramipril: suitability — Medical history and diabetes
- NHS high blood pressure — Lifestyle and condition context
- NHS blood pressure test — Measurement context
- Tritace UK SmPC, August 2026 — Product information
- Tritace leaflet, November 2020 — Dated leaflet cautions
- Altace US label, May 2026 — US product record
- SPS ACE-inhibitor monitoring — Monitoring context
- SPS ACE inhibitors and breastfeeding — Infant-specific advice
- AHA/ACC hypertension guideline, 2025 — Attributed care guidance
- HOPE original paper, 2000 — Methods and sponsorship
- Sanofi results, January 2026 — Commercial revenue
- Sanofi share and office record — Ownership and jurisdiction
- Pfizer annual review, 2025 — Commercial route
- Pfizer current fact sheet — Company location
- Pfizer acquisition of King, 2011 — Historical ownership
- AstraZeneca annual summary, 2025 — Backer business route
- AstraZeneca AGM notice, 2025 — Backer jurisdiction
- England PCA substances, 2025/26 — Prescribing context
- PCA methodology, June 2026 — Dataset limits
- MHRA Yellow Card — Reporting context
- NHSBSA accounts, 2025/26 — Institutional finance
- NHS content policy — Dated website funding policy
- SPS service commissioning — Programme financial route
- NHS England accounts, 2025/26 — Commissioner finance
- MHRA accounts, 2025/26 — Safety regulator finance
- NLM FY 2027 justification — Label-host institution finance
- NLM appropriations index — Host location and budget provenance
- NIH gift-administration policy — Gift authority, not receipt
- AHA annual report, 2024/25 — Society finance
- AHA corporate disclosure, 2024/25 — Corporate support route
- AHA fundraising notices — Society location
- ACC industry relations — Society commercial routes
- ACC contact record — Society location
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.